For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 1Y
$255.38
Thesis
Illumina remains the dominant DNA sequencing platform provider, with NovaSeq X driving a multi-year instrument refresh and consumables ramp. Post-GRAIL divestiture, the company is back to a focused tools-and-consumables business model.
The picks-and-shovels position into AI-enabled drug discovery and population-scale genomics is strong; the open questions are the pace of NovaSeq X consumables conversion and competitive pressure from Element, Ultima, and other lower-cost sequencers.
Catalysts
- NovaSeq X installed base ramp and consumables pull-through
- Margin recovery as cost actions and product mix improve
- Clinical sequencing growth (oncology and reproductive health)
- Competitive response to emerging short-read challengers
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Aug 13DealSEC
8-K filed with items 1.01, 1.02, 2.03, 9.01 covering entry/termination of material agreements and creation of financial obligation.
- Aug 12OtherSEC
Illumina filed an 8-K on 2026-08-12 disclosing other events under items 8.01 and 9.01.
- Aug 10Securities offeringSEC
Illumina filed Form 424B2 prospectus supplement for securities offering.
- Jul 30Financial resultsSEC
Illumina files 8-K with items 2.02 and 9.01 disclosing financial results.
- Jun 23LeadershipSEC
Illumina 8-K item 5.02 filed disclosing officer or director changes.